Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 10:14 AM

MediVation Inc

Type: Company
Name: MediVation Inc
First Reported 10/27/2009 - Updated 10/28/2009 - 10 Documents
Astellas Pharma Inc - Click to view 360-page
Astellas Pharma Inc
MDVN: Development and Commercialization Agreement w/Astellas for MDV3100
Astellas Pharma Inc. and Medivation, Inc. (MDVN) have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM ... [Individual.com - 10/28/2009]
First Reported 11/03/2009 - Updated 11/04/2009 - 5 Documents (in Health)
Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer’s disease (AD) ... [News-Medical.Net - 11/04/2009]
First Reported 10/28/2009 - Updated 10/29/2009 - 4 Documents
JAPAN'S ASTELLAS BUYS DEV'T,SALES RIGHTS TO PROSTATE CANCER DRUG
Japan firm Astellas Pharma Inc. (TSE:4503) said Wednesday that it has acquired the development and marketing rights to a prostate cancer treatment from U.S. start-up Medivation Inc.In the U.S., the Japanese drugmaker will team up with Medivation to develop ... [Individual.com - 10/29/2009]
First Reported 11/05/2009 - Updated 11/06/2009 - 2 Documents (in Health)
Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).The CONTACT ... [World Pharma News - 11/06/2009]
First Reported 11/05/2009 - Updated 11/05/2009 - 1 Documents (in Biology)
Astellas, Medivation to develop, commercialize MDV3100 for treatment of prostate cancer
The companies will use a compound developed in UCLA laboratoriesAstellas Pharma Inc. of Japan and California's Medivation Inc. have announced a global agreement to develop and commercialize MDV3100, a chemical compound developed in UCLA science laboratories ... [UCLA News - 11/05/2009]
First Reported 11/05/2009 - Updated 11/05/2009 - 1 Documents
Roth Capital Upgrades Medivation (MDVN) to Buy
Roth Capital upgrades Medivation (Nasdaq: MDVN) from Hold to Buy. Price target increased from $21 to $34.To see more analyst ratings on MDVN Click Here.Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for ... [Street Insider - 11/05/2009]
First Reported 11/06/2009 - Updated 11/06/2009 - 1 Documents
Pfizer Inc - Click to view image in its original context
Pfizer Inc
Medivation Lags Expectations
Medivation Inc. (MDVN) has reported a net loss of 42 cents per share in the third quarter of 2009, exceeding the Zacks Consensus Estimate of a net loss of 39 cents. However, net loss declined from the year-ago loss of 68 cents.Revenue for the quarter ... [Individual.com - 11/06/2009]
First Reported 10/29/2009 - Updated 10/29/2009 - 1 Documents
J.P. Morgan Initiates Coverage on Medivation (MDVN) with an Overweight
J.P. Morgan initiates coverage on Medivation (Nasdaq: MDVN) with an Overweight.To see more analyst ratings on MDVN Click Here.Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's ... [Street Insider - 10/29/2009]
First Reported 10/30/2009 - Updated 10/30/2009 - 1 Documents (in Biology)
Adjust-as-You-Go Trial Approach: Key to Pleasing FDA, Partners?
Such was the subject of a roundtable during the second day of the BIO Investor Forum here. Wrapping up two days before Halloween, the conference delved into a variety of challenges that haunt the industry, not the least of which involves methods of putting ... [Pharmacy Choice - 10/30/2009]
First Reported 10/23/2009 - Updated 10/23/2009 - 1 Documents (in Medicine)
Medivation, Inc. (MDVN) Names Hank Mansbach, M.D., Vice President of Medical Affairs
SAN FRANCISCO, Oct. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced the appointment of Hank Mansbach, M.D., as vice president of medical affairs. Dr. Mansbach will lead Medivation's medical affairs activities for dimebon (latrepirdine*), ... [BioSpace - 10/23/2009]
First Reported 10/28/2009 - Updated 10/28/2009 - 1 Documents
Astellas, U.S. firm to develop, commercialize prostate cancer drug
TOKYO, Oct. 28 KYODOJapanese drugmaker Astellas Pharma Inc. and Medivation Inc., a U.S. biopharmaceutical firm, said Wednesday they have agreed to develop and commercialize worldwide a drug to treat prostate cancer.Japanese drugmaker Astellas Pharma Inc. ... [Kyodo - 10/28/2009]
First Reported 10/27/2009 - Updated 10/27/2009 - 1 Documents
BRIEF-Astellas, Medivation to co-develop prostate cancer treatment
Oct 27 (Reuters) - Medivation Inc:* Astellas and Medivationco-commercialize mdv3100 for the treatment of prostate cancer* Says to receive $110 million upfront cash payment* Eligible to get $655 million in milestone payments, 50 percent of U.S.profits ... [Forbes.com - 10/27/2009]

Quotes

TOKYO and SAN FRANCISCO, Oct. 27 -- Astellas Pharma Inc. ( "Astellas') and Medivation Inc. ( NASDAQ:MDVN) announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy."
MONSTERSTOX.COM: Monsterstox.com : Medivation, Inc. (Nasdaq: MDVN) [RBC Dain Rauscher - 10/27/2009]

More Content

All (42) | News (41) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0)
sort by: Date | Relevance
Reuters Summit-Pfizer says absorbing Wyeth at t... [Forbes.com - 11/11/2009]
Medivation Lags Expectations [Individual.com - 11/06/2009]
Pfizer and Medivation Initiate Two Phase 3 Tria... [World Pharma News - 11/06/2009]
Roth Capital Upgrades Medivation (MDVN) to Buy [Street Insider - 11/05/2009]
Astellas, Medivation to develop, commercialize ... [UCLA News - 11/05/2009]
Pfizer, Medivation begin 2 phase-3 trial of dru... [PharmaBiz - 11/05/2009]
Medivation (MDVN) Reports Q3 Loss of $0.42, Mis... [Street Insider - 11/05/2009]
www.PicksThatMove.com: "Picks that move&qu... [TMC Net - 11/04/2009]
Pfizer and Medivation initiate dimebon trials i... [News-Medical.Net - 11/04/2009]
Pfizer And Medivation Initiate Two Phase 3 Tria... [Individual.com - 11/03/2009]
Pfizer, Medivation Initiate 2 Phase 3 Trials Of... [RTTNews.com - 11/03/2009]
Pfizer (PFE) And Medivation (MDVN) Initiate Two... [Street Insider - 11/03/2009]
Pfizer And Medivation Initiate Two Phase 3 Tria... [Business Wire - 11/03/2009]
Adjust-as-You-Go Trial Approach: Key to Pleasin... [Pharmacy Choice - 10/30/2009]
J.P. Morgan Initiates Coverage on Medivation (M... [Street Insider - 10/29/2009]
Concert Pharmaceuticals’ Roger Tung Awar... [Business Wire - 10/29/2009]
JAPAN'S ASTELLAS BUYS DEV'T,SALES RIGHTS TO PRO... [Individual.com - 10/29/2009]
Astellas, Medivation enter worldwide pact to co... [PharmaBiz - 10/29/2009]
Astellas plans prostate cancer drug [Japan Times - 10/29/2009]
Astellas plans prostate cancer drug [Japan Times - 10/28/2009]
MDVN: Development and Commercialization Agreeme... [Individual.com - 10/28/2009]
Medivation deal to develop prostate cancer drug [San Francisco Chronicle - 10/28/2009]
Astellas, U.S. firm to develop, commercialize p... [Kyodo - 10/28/2009]
Astellas, Medivation Enter Prostate-Cancer Drug... [FDA News - 10/27/2009]
Medivation Signs Global Deal With Astellas Phar... [RTTNews.com - 10/27/2009]
Astellas and Medivation to Co-Develop and Co-Co... [PharmaceuticalProcessing - 10/27/2009]
Early-Market Movers: Medivation, Zoran Corp. [FOXBusiness.com - 10/27/2009]
MONSTERSTOX.COM: Monsterstox.com : Medivation, ... [RBC Dain Rauscher - 10/27/2009]
Astellas Pharma Inc., Medivation, Inc. (MDVN) i... [BioSpace - 10/27/2009]
Medivation Partners With Astellas For Prostate ... [Nasdaq - 10/27/2009]
1 2
In Focus
  •  
Masafumi Nogimori (Astellas Pharma Inc), William Blair, Paul Fischer, [more]
  •  
Pfizer Inc, Astellas Pharma Inc, Zoran Corporation, [more]
  •  
Food and Drug Administration, UCLA, American Cancer Society, [more]
  •  
MDV3100, Prostate Cancer, Alzheimer's Disease, [more]
  •  
San Francisco (United States), Tokyo, Bangalore, [more]
  •  
United States, Japan, Canada, [more]
  •  
Medicine, Diseases, Biology, [more]
  •  
Pharma & Biotech, Energy, Health, [more]
Street Insider, Individual.com, PharmaBiz, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Medivation: Q1 Results Aided by Lower Operating... [Biotech Sector and Stocks Analysis from Seeking ... - 05/14/2009]
Zacks.com submits: By Brian Marckx, CFAMedivation Inc. (MDVN) reported first quarter 2009 financial results following the market close on May 11, 2009. Revenue ...
1

  •  
  •  
  •